- Home
- CZNC vs VALN Comparison
CZNC vs VALN Comparison
Compare CZNC & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | VALN |
|---|---|---|
| Founded | 1864 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.4M | 495.5M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CZNC | VALN |
|---|---|---|
| Price | $22.85 | $5.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $23.50 | $15.50 |
| AVG Volume (30 Days) | ★ 70.8K | 18.4K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | $1,139.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.16 | $5.04 |
| 52 Week High | $24.25 | $12.25 |
Technical Indicators
Market Signals| Indicator | CZNC | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 39.11 |
| Support Level | $21.28 | $5.10 |
| Resistance Level | $24.01 | $5.52 |
| Average True Range (ATR) | 0.61 | 0.20 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 51.96 | 14.00 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.